Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines
1997

Folate-Binding Protein and Cisplatin Sensitivity in Ovarian Cancer

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): F Ottonel, S Miotti, C Bottini, M Bagnoli, P Perego, M Colnaghi, S Menard

Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

Hypothesis

Is the overexpression of folate-binding protein associated with cisplatin sensitivity in ovarian carcinoma cell lines?

Conclusion

Higher levels of folate-binding protein expression are significantly associated with increased sensitivity to cisplatin in ovarian carcinoma cell lines.

Supporting Evidence

  • FBP overexpression was observed in more sensitive ovarian carcinoma cell lines.
  • Cisplatin-resistant cell lines showed decreased FBP expression.
  • FBP expression correlated significantly with cisplatin sensitivity (r = 0.68; P = 0.027).
  • Transfected cells did not show increased sensitivity to cisplatin despite higher FBP levels.

Takeaway

This study found that ovarian cancer cells with more folate-binding protein are better at responding to a cancer drug called cisplatin.

Methodology

The study used a colorimetric assay to measure cytotoxicity of cisplatin on various ovarian carcinoma cell lines and analyzed folate-binding protein expression through immunofluorescence.

Limitations

The study does not establish a direct causal relationship between folate-binding protein expression and cisplatin sensitivity.

Participant Demographics

Human ovarian carcinoma cell lines were used in the study.

Statistical Information

P-Value

p=0.027

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication